- Healthcare Movers: AI, M&A, Policy - May 7Today’s healthcare briefing covers AI-embodied surgical robotics, a $4.1B rare-disease buyout, digital therapy gains and renewed drug-pricing scrutiny under TrumpRx. Read on for what you should watch.
- Healthcare M&A, AI & Policy, May 6Bayer agreed to acquire Perfuse for up to $2.45B while AI research and payer modernization promise efficiency gains. At the same time, drug-pricing scrutiny and GLP-1 cost pressure leave the sector balanced.
- Healthcare: Interoperability, Medicare, FDA Shifts - May 6Today’s healthcare briefing covers interoperability strides, a new Medicare route to cheaper GLP-1s, federal drug policy contradictions, and FDA-driven uncertainty in gene therapy. Read on for catalysts and risks investors should watch.
- Healthcare Wrap-Up: AI, Drugs, Policy - May 5Interoperability wins and a biotech data boost shared headlines today, while public-health trends and policy scrutiny added caution. Read what moved the Healthcare sector and what you should watch next.
- Healthcare Snapshot: Interop, Hospital Aid, Biotech - May 5States weigh emergency aid as Medicaid cuts loom, while health IT interoperability and a fresh biotech $83M raise offer mixed signals. Read what you should watch today.
- Healthcare Wrap: Mixed Signals - May 4Healthcare delivered both wins and warnings today, from interoperability upgrades and promising MS and cancer data to fines for weight-loss ads and rising bankruptcies. Read what moved the sector and what you should watch next.
- Healthcare Outlook: Data, Policy, China - May 4Today’s healthcare briefing highlights interoperability and AI efforts alongside fresh policy and supply chain risks. Read what data modernization, HIPAA updates, and China rules mean for your portfolio.
- Healthcare Wrap: Tech, Research & Legal Risk - May 3Interoperability wins and new biomedical findings drove constructive headlines, but a federal appeals court ruling blocking mifepristone mailings injects regulatory risk. Markets were closed Sunday; investors should watch Monday's open.
- Healthcare: Innovation Meets Policy Headwinds - May 3Health IT modernization and promising diagnostic and GLP-1 data are balancing a major court ruling that limits abortion-pill mailing. Read what you should watch heading into the May 4 session.
- Healthcare Wrap-Up May 2Mixed signals dominated the healthcare sector heading into the long weekend. Tech and biology advances met a major regulatory setback on the abortion pill, leaving you with selective opportunities and risks.
- Healthcare Momentum: Approvals and Interop Wins - May 2FDA approvals for a new Merck HIV pill and Arvinas/Pfizer breast cancer drug headline fresh momentum in healthcare, while interoperability and payer modernization advance. Read what you should watch heading into the long weekend.
- Healthcare Wrap-Up: Innovation and Headwinds - May 1Today’s healthcare news mixed tech wins and biotech drama. Interoperability and device advances shared the stage with a trial stumble, an FDA panel setback, and a recall. Read what matters for markets tomorrow.
- Healthcare Roundup: Tech, IPOs and Policy - May 1Healthcare investors face a mixed start to May, with health IT interoperability gains and big biotech IPOs balanced against visa delays that threaten doctor placement and equity concerns in new therapies. Here’s what you need to know for today.
- Healthcare Wrap Apr 30Today’s healthcare headlines mixed big-tech interoperability wins and AI diagnostic advances with strategic insurer moves and cautious drug data. Read the evening wrap to see what matters to you tomorrow.
- Healthcare: Interop, Brain Science & Policy - Apr 30Health IT interoperability and new neuroscience findings headline a mixed healthcare morning. Policy shifts on Medicaid and disaster access for addiction meds add uncertainty for payers and providers.
- Healthcare Wrap: IT Momentum Meets Access Gaps - Apr 29Health IT and interoperability stories dominated today even as studies highlighted long neurology wait times and equity gaps. Financials at UHS and Humana show near-term pressure but managements are signaling recovery plans.
- Healthcare Tech, Policy and Science - Apr 29Healthcare headlines today span interoperability wins for payers, new AI and mRNA research, and policy shifts on Medicaid and FDA oversight. Read what you should watch in the session ahead.
- Healthcare Wrap-Up: Data, Trials, Centene Beat - Apr 28Insurer Centene lifted 2026 profit guidance after a strong Q1, while the FDA and industry pilots push real-time, AI-enabled clinical trials. Health IT interoperability and new clinical endpoints keep momentum building.
- Healthcare: AI, Rural Fund, and Policy Risks - Apr 28A $50B federal rural health program and renewed interoperability pushes are shaping healthcare tech and policy headlines today. You should watch contractor awards, AI safety updates from $GOOGL, and near-term policy risks.
- Healthcare Upbeat on Trials and Tech - Apr 27Clinical wins from Erasca, a pooled cord-blood transplant study, and a promising psoriasis candidate lifted sentiment today, while interoperability and policy stories set the operational backdrop.
- Healthcare Snapshot Apr 27: Interop, FDA NodInteroperability projects and an FDA nod for a neurotech implant headline a mixed morning for healthcare. Coverage gaps and new research underscore long-term cost and demand pressures.
- Healthcare Innovation and IT Progress - Apr 26Advances in interoperability, computational drug discovery and immune-targeting antibodies led today's healthcare headlines. Heading into the Monday session, investors will watch which firms and payers can commercialize these technology and research gains.
- Healthcare Highlights: AI, FDA Psychedelics - Apr 26Health IT modernization, new AI-driven clinical findings, and the FDA’s faster path for three psychedelics headline the healthcare beat. Here’s what you need to know heading into the long weekend.
- Healthcare Wrap: Innovation and Policy - Apr 25Health IT interoperability, a wool-based bone repair breakthrough, and faster FDA reviews for psychedelics drove sector headlines. Read what matters heading into the Apr 27 session.
- Healthcare Briefing: Tech, Psychedelics, Research - Apr 25Healthcare IT modernization, FDA moves on psychedelics, and new biomedical research set the agenda heading into the long weekend. Read what mattered and what you should watch next.
- Healthcare Wrap-Up Apr 24Today's healthcare headlines mix scientific wins and regulatory shifts with commercial pain. From faster FDA reviews for psychedelics to proteomics breakthroughs and a rough week for $LLY, readers should weigh progress against execution and safety risks.
- Healthcare: Gene Therapy Win, System Strains - Apr 24A landmark U.S. approval for a gene therapy and a White House push on psychedelics compete with worsening ED boarding, climate-linked cardiac risks, and scrutiny of research quality. Read what you should watch today.
- Healthcare: Gene Therapy Win, Research Upgrades - Apr 23Regeneron scored an FDA approval for a hearing-loss gene therapy while AbbVie committed $1.4B to U.S. manufacturing. Academic advances in oncology and neurodegeneration add pipeline tailwinds.
- Healthcare Mixed Signals on Policy and Innovation - Apr 23Policy pressure over benefits and rising Medigap premiums compete with fresh clinical and tech advances. Today’s brief covers patient costs, telehealth scrutiny, new research and cybersecurity trends.
- Healthcare Wrap Apr 22: Innovation, Policy, CostsToday brought breakthroughs in brain imaging and promising oncology data alongside rising post-arbitration prices and policy scrutiny. The healthcare story is a mixed bag for investors, with selective opportunities and near-term risks to monitor.
- Healthcare Roundup: Research, Costs, Policy - Apr 22Biotech funding and fresh science headlines share the spotlight with policy and cost pressures. Read what you need to know this morning and which catalysts could move healthcare stocks today.
- Healthcare Mixed Signals: Research & Earnings Apr 21Today's healthcare flow mixed breakthrough research and startup funding with a big oncology trial failure and a strong earnings beat from UnitedHealth. Read what moved stocks, which catalysts matter next, and how you might prioritize risks.
- Healthcare Mixed Signals - Apr 21Morning briefing: coffee and CAR-T research offer scientific upside while policy fights over federal health data and concerns about REIT-run nursing homes raise risk. Read what you should watch today.
- Healthcare Rally on M&A, CAR-T Wins - Apr 20M&A, clinical readouts and diagnostic advances drove a positive tone in healthcare today. Lilly's Kelonia buyout, promising CAR-T prevention data, and Nektar's extension results stood out.
- Healthcare: Innovation vs Policy Pressure - Apr 20A promising NYU-led study shows gut microbial fingerprints can predict melanoma relapse with up to 94% accuracy, while regulators, PBMs and courts press the sector on pricing and practices. Today’s brief looks at the research upside, legal and policy headwinds, and what you should watch this week.
- Healthcare Momentum from Drugs to Policy - Apr 19Breakthrough drug data for pancreatic cancer and a novel diabetic wound therapy drove optimism for biotech, while federal moves to expand psychedelic access add a policy tailwind. Operational and regulatory questions mean selectivity is key heading into Apr 20.
- Healthcare Breakthroughs Drive Momentum - Apr 19Revolution Medicines' daraxonrasib headline a wave of biotech and health-tech progress heading into Apr 20. Policy shifts on psychedelics and new neural sensors add potential catalysts for selective healthcare names.
- Healthcare Wrap Apr 18: Innovation, Policy and ITResearch on mRNA cancer vaccines and short therapy wins for pediatric lupus shared the headlines while federal moves on psychedelics and CDC leadership added regulatory uncertainty. IT best practices for EHR downtime and administrative playbooks rounded out a day of mixed but material developments heading into the long weekend.
- Healthcare Snapshot: M&A, Obesity Buzz & Policy - Apr 18A quiet markets weekend belies fresh healthcare developments: UCB's up-to-$1.2B deal for Neurona, widespread buzz around retatrutide and policy shifts at the CDC and state level. Read what you should watch heading into Monday.
- Healthcare Wrap Apr 17: Trials, Policy, SafetyClinical optimism at Revolution Medicines and a $4M HHS KidneyX prize contrasted with safety questions around GLP-1s and a CMS reimbursement proposal. Read what moved health stocks today and what to watch next.
- Healthcare Mixed Signals: Breakthroughs and Risks - Apr 17Today’s healthcare briefing combines a first-in-human transplant breakthrough, expanding AI and 5G deployments, and renewed concerns about therapy chatbots and cybersecurity. Read what you should watch in trading today.
- Healthcare Innovation Meets Public Health Worries - Apr 16Today brought breakthroughs in oncology and AI-enabled genomic testing alongside public-health studies linking sleep loss and hidden viruses to worse outcomes. You’ll find what moved the sector, which companies were in the headlines, and the catalysts to watch for tomorrow.
- Healthcare: Policy, AI and Science - Apr 16Federal Medicaid work rules, a critical Alzheimer’s review, and new AI partnerships lead a mixed healthcare morning. Read what drove overnight headlines and what to watch today.
- Healthcare Sector Roundup - Apr 15CMS proposes rolling back device payment flexibilities while Beeline launches with $300M and Abridge inks NEJM and JAMA deals. Research and operational items add mixed signals for investors.
- Healthcare: AI, Diagnostics, Rural Strain - Apr 15Today’s headlines balance scientific advances and widening access pressures across healthcare. New diagnostics and AI screening promise opportunities while closures, coverage losses, and reimbursement questions keep risks front and center.
- Healthcare Evening Wrap, Apr 14Travere wins FDA approval for Filspari and $JNJ posts stronger-than-expected drug sales, while AI and immersive tech face adoption hurdles. Here's what you need to know for tomorrow.
- Healthcare Advances Highlight Innovation - Apr 14Breakthroughs in diagnostics for cancer, Alzheimer’s and tuberculosis led healthcare headlines today, while hospitals and digital health pilots reshape care delivery. Read what you should watch next.
- Healthcare Breakthroughs Dominate Apr 13Today’s healthcare news was dominated by clinical breakthroughs, from an HIV remission case to late-stage oncology wins, alongside policy moves for digital care. Read what moved the sector and what you should watch next.
- Healthcare Sector: Innovation & Policy - Apr 13Today’s healthcare briefing highlights automation, connected devices, and payer strategy shifts that could reshape margins and care pathways. You’ll also want to watch FDA leadership moves and environmental policy risk for regional providers.
- Healthcare Roundup: Research & Policy - Apr 12Clinical and preclinical advances in heart failure nutrition, osteoarthritis and RSV drew attention alongside policy and public health debates. Read what this means for healthcare investors as markets reopen Monday.